The pace of AI continues to be staggering. From simple pattern recognition systems to large language models (LLMs), and now as we move into the physical AI reality, the power of these systems ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Shares of clinical-stage biotechnology company Recursion Pharmaceuticals (NASDAQ: RXRX) soared 11.43% on Wednesday, significantly outperforming the broader market. The rally followed a major analyst ...
On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...
I am participating in Hactoberfest 2025. Currently recursion is under coming soon. I can design the cards on fundamental recursion problems and design call stack and tree. If you find this issue ...
These are direct-prediction models trained from scratch on small, heavily augmented datasets—not few-shot prompting. ARC remains the canonical target; broader leaderboard context and rules (e.g., ...
This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...
Visualize recursion in real-time — watch the call stack grow & shrink with stack and tree views. Built with HTML, CSS, JS (Canvas).
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results